Single-Cell and Plasma Proteomics Do Not Differentiate Patients With and Without SARS-CoV-2 Antigenemia in Convalescence in a Cohort of 100 Patients - Scorecard - MDSpire
Advertisement
Single-Cell and Plasma Proteomics Do Not Differentiate Patients With and Without SARS-CoV-2 Antigenemia in Convalescence in a Cohort of 100 Patients
Clinical Scorecard: Proteomic Analysis of Single Cells and Plasma Fails to Distinguish Between SARS-CoV-2 Antigenemia and Non-Antigenemia Patients During Convalescence in a Study of 100 Individuals
At a Glance
Category
Detail
Condition
Post-acute SARS-CoV-2 infection and Long COVID (LC)
Key Mechanisms
Persistence of SARS-CoV-2 antigens (S1, spike, N) in plasma; immune dysregulation; viral antigenemia
Target Population
Individuals recovering from acute SARS-CoV-2 infection, including those with and without Long COVID symptoms
Care Setting
Outpatient convalescent follow-up and research settings
Key Highlights
SARS-CoV-2 antigens detected in plasma up to 12 months post-infection in 14% of patients.
No significant differences in plasma proteins or immune cell protein expression between antigenemic and non-antigenemic patients.
Antigenemia rates did not correlate with presence or absence of Long COVID symptoms.
Guideline-Based Recommendations
Diagnosis
Use of single molecule array (Simoa) assays to detect SARS-CoV-2 S1, spike, and N antigens in plasma during convalescence.
Management
No current evidence supports using plasma antigenemia status to guide Long COVID management.
Antiviral treatment (e.g., remdesivir) during acute infection may reduce early antigenemia but effect not sustained at 12 months.
Monitoring & Follow-up
Longitudinal assessment of symptoms and plasma antigen levels at 3 and 12 months post-infection.
Symptom questionnaires, interviews, and physical exams recommended for Long COVID evaluation.
Risks
Persistent antigenemia detected in some recovered patients without clear clinical consequences.
No increased risk of Long COVID symptoms associated with antigenemia identified.
Patient & Prescribing Data
100 patients assessed approximately 3 and 12 months after acute SARS-CoV-2 infection, including vaccinated and unvaccinated individuals.
Remdesivir during acute infection associated with lower antigenemia at 3 months but not at 12 months; vaccination status did not affect antigenemia rates at 12 months.
Clinical Best Practices
Assess Long COVID symptoms comprehensively using standardized definitions and multi-modal evaluations.
Interpret plasma antigenemia cautiously as it does not distinguish Long COVID status or immune dysregulation.
Consider antiviral treatment during acute infection as potentially reducing early antigen persistence.
Continue research to elucidate the clinical significance of persistent SARS-CoV-2 antigenemia.
A global systematic review of 173 studies found differing associations between COVID-19 infection and vaccination and retinal vascular events, with retinal artery occlusion more common after infection and retinal vein occlusion more common after vaccination.
